Related references
Note: Only part of the references are listed.On-Chip Synthesis and Screening of a Sialoside Library Yields a High Affinity Ligand for Siglec-7
Cory D. Rillahan et al.
ACS CHEMICAL BIOLOGY (2013)
C-4 Modified Sialosides Enhance Binding to Siglec-2 (CD22): Towards Potent Siglec Inhibitors for Immunoglycotherapy
Sorge Kelm et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2013)
Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook
Loretta Sullivan-Chang et al.
BIODRUGS (2013)
Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis
Matthew S. Macauley et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Copresentation of Antigen and Ligands of Siglec-G Induces B Cell Tolerance Independent of CD22
Fabian Pfrengle et al.
JOURNAL OF IMMUNOLOGY (2013)
CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
Elizabeth M. Bradshaw et al.
NATURE NEUROSCIENCE (2013)
Alzheimer's Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Ana Griciuc et al.
NEURON (2013)
Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation
Norihito Kawasaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Click and Pick: Identification of Sialoside Analogues for Siglec-Based Cell Targeting
Cory D. Rillahan et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Roland B. Walter et al.
BLOOD (2012)
From a Library of MAG Antagonists to Nanomolar CD22 Ligands
Stefanie Mesch et al.
CHEMMEDCHEM (2012)
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
Robert J. Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
In Silico-Aided Design of a Glycan Ligand of Sialoadhesin for in Vivo Targeting of Macrophages
Corwin M. Nycholat et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Hagop Kantarjian et al.
LANCET ONCOLOGY (2012)
Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions
Takumi Kiwamoto et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Targeting Siglecs-A novel pharmacological strategy for immuno- and glycotherapy
Camilla Jandus et al.
BIOCHEMICAL PHARMACOLOGY (2011)
CD22-Antagonists with nanomolar potency: The synergistic effect of hydrophobic groups at C-2 and C-9 of sialic acid scaffold
Hajjaj H. M. Abdu-Allah et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
High affinity sialoside ligands of myelin associated glycoprotein
Ying Zeng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
A Sialylated Glycan Microarray Reveals Novel Interactions of Modified Sialic Acids with Proteins and Viruses
Xuezheng Song et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells
Mary K. O'Reilly et al.
JOURNAL OF IMMUNOLOGY (2011)
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease
Adam C. Naj et al.
NATURE GENETICS (2011)
In vivo targeting of B-cell lymphoma with glycan ligands of CD22
Weihsu C. Chen et al.
BLOOD (2010)
Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
Michinori Ogura et al.
CANCER SCIENCE (2010)
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Anjali Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo
Bao Hoa Duong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Low Molecular Weight Antagonists of the Myelin-Associated Glycoprotein: Synthesis, Docking, and Biological Evaluation
Stefanie Mesch et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Potent small molecule mouse CD22-inhibitors: Exploring the interaction of the residue at C-2 of sialic acid scaffold
Hajjaj H. M. Abdu-Allah et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Siglecs as targets for therapy in immune-cell-mediated disease
Mary K. O'Reilly et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Basic and Clinical Immunology of Siglecs
Stephan von Gunten et al.
YEAR IN IMMUNOLOGY 2008 (2008)
Design, Synthesis, and Structure-Affinity Relationships of Novel Series of Sialosides as CD22-Specific Inhibitors
Hajaj H. M. Abdui-Allah et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Sialoside analogue arrays for rapid identification of high affinity siglec ligands
Ola Blixt et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)
Siglecs and their roles in the immune system
Paul R. Crocker et al.
NATURE REVIEWS IMMUNOLOGY (2007)
High-affinity ligand probes of CD22 overcome the threshold set by cis ligands for binding, endocytosis, and killing of B cells
Brian E. Collins et al.
JOURNAL OF IMMUNOLOGY (2006)
One-pot three-enzyme chemoenzymatic approach to the synthesis of sialosides containing natural and non-natural functionalities
Hai Yu et al.
NATURE PROTOCOLS (2006)
Highly efficient chemoenzymatic synthesis of naturally occurring and non-natural alpha-2,6-linked sialosides: A P. damsela alpha-2,6-sialyltransferase with extremely flexible donor-substrate specificity
Hai Yu et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2006)
Printed covalent glycan array for ligand profiling of diverse glycan binding proteins
O Blixt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Sialoside specificity of the siglec family assessed using novel multivalent probes - Identification of potent inhibitors of myelin-associated glycoprotein
O Blixt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound
S Kelm et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
RJ Kreitman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
